| Literature DB >> 30150207 |
Zhuting Hu1, Annabelle J Anandappa1,2, Jing Sun1, Jintaek Kim1, Donna E Leet1,2, David J Bozym1,2, Christina Chen1, Louise Williams3, Sachet A Shukla1,3,4, Wandi Zhang1, Diana Tabbaa3, Scott Steelman3, Oriol Olive1, Kenneth J Livak4, Hiroyuki Kishi5, Atsushi Muraguchi5, Indira Guleria6, Jonathan Stevens6, William J Lane2,6, Ute E Burkhardt1, Edward F Fritsch1,3, Donna Neuberg7, Patrick A Ott1,2,8, Derin B Keskin1,2,3,8, Nir Hacohen2,3,9, Catherine J Wu1,2,3,8.
Abstract
Recent studies have highlighted the promise of targeting tumor neoantigens to generate potent antitumor immune responses and provide strong motivation for improving our understanding of antigen-T-cell receptor (TCR) interactions. Advances in single-cell sequencing technologies have opened the door for detailed investigation of the TCR repertoire, providing paired information from TCRα and TCRβ, which together determine specificity. However, a need remains for efficient methods to assess the specificity of discovered TCRs. We developed a streamlined approach for matching TCR sequences with cognate antigen through on-demand cloning and expression of TCRs and screening against candidate antigens. Here, we first demonstrate the system's capacity to identify viral-antigen-specific TCRs and compare the functional avidity of TCRs specific for a given antigen target. We then apply this system to identify neoantigen-specific TCR sequences from patients with melanoma treated with personalized neoantigen vaccines and characterize functional avidity of neoantigen-specific TCRs. Furthermore, we use a neoantigen-prediction pipeline to show that an insertion-deletion mutation in a putative chronic lymphocytic leukemia (CLL) driver gives rise to an immunogenic neoantigen mut-MGA, and use this approach to identify the mut-MGA-specific TCR sequence. This approach provides a means to identify and express TCRs, and then rapidly assess antigen specificity and functional avidity of a reconstructed TCR, which can be applied for monitoring antigen-specific T-cell responses, and potentially for guiding the design of effective T-cell-based immunotherapies.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30150207 PMCID: PMC6213317 DOI: 10.1182/blood-2018-04-843763
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113